Dogwood Therapeutics Inc expected to post a loss of 14 cents a share - Earnings Preview
Dogwood Therapeutics Inc <DWTX.OQ> expected to post a loss of 14 cents a share - Earnings Preview
Dogwood Therapeutics Inc DWTX.OQ DWTX.O is expected to show no change in quarterly revenue when it reports results on August 11 (estimated) for the period ending June 30 2026
LSEG's mean analyst estimate for Dogwood Therapeutics Inc is for a loss of 14 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Dogwood Therapeutics Inc is $13.50, about 671.4% above its last closing price of $1.75
This summary was machine generated August 7 at 11:10 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Recent news on Dogwood Therapeutics
See all newsDogwood Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Dogwood Therapeutics Q2 net loss widens on higher costs, impairment charge
Brief: Dogwood Therapeutics Q2 EPS USD -0.34
Dogwood Therapeutics Inc expected to post a loss of 14 cents a share - Earnings Preview
Brief: Dogwood Therapeutics Announces Commencement Of Halneuron® Chemotherapy Induced Neuropathic Pain Phase 2B Long Term Extension Study